FibroGen, Inc. (FGEN)

1,1300 -0,2400 (-17,52%) Al cierre: 04:00PM EDT

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 486

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Thane Wettig	CEO & Director	941,79k	N/A	1965
Mr. Juan Graham	Senior VP & CFO	892,49k	N/A	1977
Ms. Christine L. Chung	Senior Vice President of China Operations	915,36k	N/A	1968
Dr. Barry A. Berkowitz Ph.D.	Founder	N/A	N/A	N/A
Dr. John J. Hunter Ph.D.	Chief Scientific Officer	N/A	N/A	1963
David DeLucia	Vice President of Corporate FP&A and Investor Relations	N/A	N/A	N/A
Mr. Michael D. Lowenstein J.D., Ph.D.	Chief Legal Officer	N/A	N/A	N/A
Ms. Tricia Stewart	Chief People Officer	N/A	N/A	N/A
Mr. Kirk A. Christoffersen MBA	Chief Business Officer	N/A	N/A	1969
Dr. Rahul Rajan Kaushik Ph.D.	Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Gobierno corporativo

El ISS Governance QualityScore de FibroGen, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 2; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.